Connect with us
DAPA Banner

Business

Finance expert says record debt is locking young Americans out of housing

Published

on

Finance expert says record debt is locking young Americans out of housing

Young Americans are increasingly finding themselves shut out of the housing market as rising debt levels and lingering affordability pressures reshape the path to homeownership.

“The Ramsey Show” host Dave Ramsey joined FOX Business’ Cheryl Casone on the FOX Business In Depth Special, “Hitting Home: Rebuilding the Dream,” to break down the financial realities facing first-time buyers and why many are falling behind.

Advertisement

Ramsey pointed to a combination of record-high consumer debt and shifting economic conditions that have eroded buying power across younger generations.

“I’m afraid I have to tell you the truth… Corporate America has screwed you,” Ramsey said. 

“Car debt is at an all-time high… Student loan debt is at an all-time high… And, of course, credit card debt… is at a all-time high.”

Advertisement
For sale sign in front of a house

For sale sign in front of a house in Houston, Texas. (Kirk Sides/Houston Chronicle / Getty Images)

MIAMI OVERTAKES LOS ANGELES AND NEW YORK AS WORLD’S RISKIEST HOUSING MARKET FOR BUBBLE RISK

Those pressures, he explained, are leaving many without the financial flexibility to enter the housing market, as disposable income is increasingly consumed by monthly obligations.

“When you’re drowning in personal debt, you can’t afford to buy a freaking house,” Ramsey said.

Beyond debt, Ramsey also highlighted the post-pandemic housing surge as a key factor pushing first-time-buyer ages higher, noting that supply shortages and elevated prices continue to weigh on affordability.

MORTGAGE RATES JUMP TO HIGHEST LEVEL IN OVER 3 MONTHS

Despite the challenges, Ramsey pushed back on the idea that homeownership is out of reach, arguing that progress is still possible for those willing to aggressively tackle debt.

“Our message to Gen Z and to millennials… is: clear this debt, get rid of the stupidity, and chop up the cards and work your way through it… Once you do that, you can get there,” Ramsey said.

Advertisement

CLICK HERE TO GET FOX BUSINESS ON THE GO

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Restaurants add protein, fiber for weight loss drug users

Published

on

Restaurants add protein, fiber for weight loss drug users

A mini burger, mini fries and mini beer, Clinton Hall’s “Teeny Weeny Mini Meal”, is pictured next to a regular-sized combo on Dec. 8, 2025 in New York City. Approximately one in eight American adults are currently taking drugs from the class of GLP-1 agonists that are now popular for weight loss, according to a November poll by the non-profit health policy tracker KFF. Some in the restaurant industry are taking note.

Angela Weiss | AFP | Getty Images

The cost of GLP-1 drugs is falling, and pill versions are hitting the U.S. market. For restaurant chains and snacking giants, higher adoption of weight loss and diabetes treatments poses a threat to their sales — or an opportunity.

Advertisement

GLP-1 drugs slow digestion, suppress users’ appetites and increase satiety. For many restaurants and packaged food manufacturers, those reactions will likely mean weaker sales. Adults who use GLP-1s consume 21% fewer calories and spend nearly a third less on grocery bills on average, according to KPMG. JPMorgan estimates the growing use of the medications could wipe out $30 billion to $55 billion in annual sales for the food and beverage industry as soon as 2030.

About one in every eight U.S. adults is currently taking a GLP-1 drug like Ozempic or Zepbound, according to the KFF Health Tracking Poll conducted from Oct. 27 to Nov. 2. That number doesn’t include consumers who have discontinued their use of the drugs; 18% of respondents said that they have taken a GLP-1 medication at some point.

Those numbers are expected to keep climbing, especially after Novo Nordisk launched its Wegovy pill in January and Eli Lilly prepares to roll out its own oral drug this year. By 2030, more than 30 million Americans could be on a GLP-1 treatment, up from 10 million in 2026, based on J.P. Morgan estimates.

Michael Siluk | UCG | Universal Images Group | Getty Images

Advertisement

But the shift also presents an opportunity for restaurants and food and beverage companies.

With new protein- and fiber-rich options, many businesses are hoping to win over GLP-1 consumers and mollify investors’ concerns about how the treatments will affect their bottom lines.

“Whether it is labeling as GLP-1 friendly, decreasing the serving size, emphasizing protein content, or even when you shift over to the beverage world, because hydration is certainly a concern, there are a number of players that are starting to react to this,” said Don K. Johnson, principal of strategy and execution for EY-Parthenon.

Skipping snacks and breakfast

About half of GLP-1 users report consuming fewer calories while taking the medications, according to UBS Evidence Lab. But the effects aren’t even across the industry, and “certain categories are more impacted than others,” Johnson said.

Advertisement

Snacking, once one of the fastest-growing grocery segments, has taken the biggest hit. About 70% of GLP-1 users who report consuming fewer calories said that they are snacking less, according to a survey conducted by EY-Parthenon last spring.

“I think it is about the specific type of snack, but I do think they’re also snacking less … Having said that, we do see that there is a shift to healthier foods, and that certainly will include healthier snacking,” Johnson said.

Think more yogurt, nuts or fruit, and fewer chips or pretzels.

Since GLP-1 drugs lead patients to lower their caloric intake, every calorie consumed means more. Protein intake is more important to prevent muscle loss. So, too, is fiber to support gut health and digestion. And staying hydrated helps mitigate some of the drugs’ side effects, like nausea and headaches.

Advertisement

The effects of eating less extend to restaurants. About 60% of those respondents to the EY-Parthenon survey said that they are dining out less frequently.

The shift could also hit full-service restaurants where diners order a drink with their meals. Roughly 45% of survey respondents who are eating and drinking less said that they are drinking less alcohol.

Surveys conducted by Bernstein indicate that the frequency of restaurant visits among GLP-1 users can fall by as much as 45%, depending on the category of food and the nature of the occasion, analyst Danilo Gargiulo of Bernstein wrote in a research note published on Tuesday.

The pullback in restaurant visits isn’t spread evenly across times of day, according to Dana Baggett, executive director of restaurant client strategy at RRD, which works with more than 200 restaurant brands.

Advertisement

Lunch, so far, hasn’t been impacted, she said. But breakfast has taken a hit, particularly from high-income GLP-1 users, who represent a bigger percentage of current patients, she said. In practice, that means fewer sugary coffee drinks and doughnuts, although options like Starbucks‘ protein cold foam could encourage those consumers to return.

A commercial for GLP-1 drugs during the Super Bowl LX broadcast on television screens at a bar in Los Angeles, California, US, on Sunday, Feb. 8, 2026.

Jill Connelly | Bloomberg | Getty Images

Dinner, especially at fast-food restaurants, has taken the brunt of the damage so far.

Advertisement

Dinner traffic has fallen 6% among consumers who have been taking the medication regularly, according to Baggett; in other words, overall restaurant sales during dinner hours have declined about 0.4% due to GLP-1 use, she said. But as the number of consumers who use the drug consistently grows, so too will the pressure on restaurant traffic.

And snacking isn’t confined to grocery store aisles. For limited-service restaurants, like McDonald’s or Taco Bell, snacking accounts for 12% of spending, according to Bank of America Global Research.

Even so, threats to those large restaurants chains may only be gradual, which gives them time to adapt.

“I think there shouldn’t be this panic out there in the marketplace, but this is a trend that’s not going away,” Baggett said. “This is an amazing opportunity for brands to start repositioning themselves and focusing on what consumers want: less sugar, higher protein and that focus on fiber.”

Advertisement

How Big Food is evolving

If recent earnings conference calls are any example, restaurant and food executives also think that it isn’t time to panic just yet. For some companies, the trend offers a chance to reach new customers through healthier options.

“I think there are more opportunities than threats, but there are both,” PepsiCo CEO Ramon Laguarta told Wall Street analysts on the company’s earnings conference call in early February.

In recent months, Pepsi has released protein-packed Doritos, relaunched Gatorade and unveiled fiber-rich varieties of SunChips and Smartfood popcorn. Those moves are part of the company’s broader strategy to modernize its portfolio and boost sales by appealing to health-conscious consumers, but they also align with Laguarta’s assumption that GLP-1 medications will be adopted more broadly.

Domino’s Pizza CEO Russell Weiner sounded unshaken when he told analysts last month that the pizza chain hasn’t seen GLP-1 drugs affect its sales yet.

Advertisement

“Dinner, for us, is a sharing occasion, so perhaps that’s why we’re not seeing any impact, but we’re going to continue to watch it,” he said. “But if there needs to be menu innovation around that, we will do that.”

RRD’s Baggett told CNBC that she thinks portions and snack sizing will be key for restaurants to attract consumers who are on GLP-1 treatments.

When asked about the drugs on McDonald’s earnings conference call last month, CEO Chris Kempczinski touted the burger chain’s existing protein options. But he added that the preferences of GLP-1 users are also being considered as the chain creates new menu items.

“We’re also seeing changes around maybe less snacking, changes in some of the beverages that they drink, less sugary drinks, and so all of those things are factoring into some of what we’re out there experimenting with and testing with,” he said.

Advertisement

Other restaurant chains have already launched options that appeal to diners on GLP-1 drugs, even if the medications weren’t the key impetus. For example, Chipotle launched grab-and-go protein cups in December, aiming to cash in on the protein and snacking crazes as its restaurant sales struggled.

And Olive Garden, owned by Darden Restaurants, released a Lighter Portions menu last year, downsizing a handful of its classic entrees at a lower price. Darden CEO Rick Cardenas said that the chain introduced the new menu to give all of its customers more options.

“It just so happens to benefit the consumers that might want smaller portions that are on GLP-1 medications, and we have a lot of options like that in all of our menus,” Cardenas said on the company’s earnings conference call in December.

Marketing to GLP-1 users

Other companies have explicitly appealed to GLP-1 users, particularly when it comes to innovation.

Advertisement

In 2024, Nestle led the pack when it launched Virtual Pursuit, a frozen-food brand targeting GLP-1 users. While the packaging initially didn’t call out that it was “GLP-1 friendly,” the food company updated it later to include it prominently, boosting sales.

“It’s a big initiative for Nestle,” Nestle USA CEO Marty Thompson told CNBC at a media event earlier in March. “There will be those things that are designed for GLP-1, and there will be those things that will be sort of a companion to GLP-1, clearly calling out protein and fiber, but not necessarily designed portion-size wise or whatever for GLP-1.”

Nestle’s focus will extend beyond food, too. Thompson said that the company plans to expand into beverages and listed protein shakes as one potential way to appeal to GLP-1 customers.

Even food companies without much exposure to GLP-1 users are broadening their portfolios to reach them.

Advertisement

Close-up view of Dippin’ Dots ice cream cup in a person’s hand, Santa Cruz, California, June 22, 2024.

Smith Collection | Gado | Archive Photos | Getty Images

For example, Dippin’ Dots and Icee owner J&J Snack Foods makes most of its sales in stadiums, theme parks and malls. Because of its “experiential” focus, CEO Dan Fachner told CNBC that he thinks that J&J is more insulated from the effect of GLP-1 drugs compared with its snacking peers.

“I still think that in most cases, even people on GLP-1 drugs will still use those occasions for snacking,” he said.

Advertisement

Even still, more than a year ago, Fachner presented employees with a challenge for the company’s grocery business, which accounts for 13.5% of annual sales.

“Take the core products — pretzels and churros and Icees and Dippin’ Dots and frozen novelties — tell me how we can make them more GLP-1 friendly as it continues to grow,” he said.

This year, J&J has a number of new products hitting the freezer aisle. Protein has been added to its soft pretzels, now available in a smaller portion size. And Luigi’s Italian Ice, traditionally sold in a cup, will come in a “mini pop size,” with a formula that includes more antioxidants or helps hydration, according to Fachner. If the new products succeed in grocery stores, then J&J plans to take them to the company’s food service customers, as well.

J&J’s new products also have the benefit of appealing to a wider audience than just consumers who are on GLP-1 medication. For example, Fachner expects the new Luigi’s mini pops will appeal to health-conscious moms as a snack for their kids.

Advertisement

Uptake could change strategies

For restaurants and food suppliers, current data on the eating and drinking habits of GLP-1 users are informing their efforts to appeal to those consumers. But that behavior can still fluctuate.

About 5% of users lapse in taking the medications, due to cost, side effects or hitting their weight goal. After quitting, they tend to maintain the same eating habits for a couple of months before eventually returning to a higher caloric intake.

“I think that we don’t spend enough time talking about the fact that there may be sort of a cycle of behaviors — people going on and off of the drugs — that will have sort of an interesting impact on manufacturers of food because there’s no ‘before’ and ‘after,’” EY’s Johnson said. “It’s a process.”

And a whole new group of consumers could soon be taking daily pill versions of GLP-1 medications. It’s too soon to tell if oral GLP-1 drugs will result in more consistent usage or higher quit rates and to know who exactly is trying the pill version over the injectable.

Advertisement

“I don’t have a crystal ball, but my guess is from our survey that the folks using the oral version of the drug will be a new set of people, because one of the barriers to trial was — as can be expected — a lot of people don’t like to take shots of injections,” Johnson said.

There is one prediction that is widely accepted: the pill version will mean much higher adoption of GLP-1 drugs.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

General Mills: A Gradual Shift In Narrative, But Not A Quick Turnaround

Published

on

General Mills: A Gradual Shift In Narrative, But Not A Quick Turnaround

General Mills: A Gradual Shift In Narrative, But Not A Quick Turnaround

Continue Reading

Business

Type 1 Diabetes Linked to Nearly Triple Dementia Risk in Large U.S. Study, Outpacing Type 2

Published

on

Deadly Meningococcal Outbreak in Kent Claims Two Lives, Sparks Vaccine

BOSTON — People with type 1 diabetes face nearly three times the risk of developing dementia compared with those without diabetes, according to a large new U.S. cohort study published March 18, 2026, in *Neurology*, the medical journal of the American Academy of Neurology. The findings highlight a stronger association for type 1 than for type 2 diabetes and raise concerns as advances in care allow more individuals with type 1 to reach older ages.

type 1 and type 2 diabetes
type 1 and type 2 diabetes

Led by Jennifer Weuve, MPH, ScD, of Boston University School of Public Health, the research drew on data from the National Institutes of Health’s All of Us Research Program, analyzing electronic health records and surveys from 283,772 adults aged 50 and older (mean age 65, 57% women). Of these, 5,442 (1.9%) had type 1 diabetes and 51,511 (18.2%) had type 2. An algorithm distinguished diabetes types, validated against self-reports and C-peptide levels.

Over an average 2.4-year follow-up (2017–2023), 2,348 participants (0.83%) developed dementia. Incidence rates were 2.6% among those with type 1 diabetes, 1.8% with type 2 and 0.6% without diabetes. After adjusting for sociodemographic factors — age, sex, race/ethnicity, education and household income — the hazard ratio for all-cause dementia was 2.82 (95% CI 2.28-3.48) for type 1 diabetes and 2.08 (95% CI 1.87-2.31) for type 2, relative to no diabetes.

The elevated risk held across genders, racial/ethnic groups and persisted even after accounting for lifestyle factors like smoking and alcohol use in supplementary analyses. Researchers estimated that about 65% of dementia cases among people with type 1 diabetes could be attributed to the condition itself.

“We have known that type 2 diabetes is linked to an increased risk of dementia, but this new research suggests that, unfortunately, the association may be even stronger for those with type 1 diabetes,” Weuve said in a statement. “As advances in medical care have extended the lives of people with type 1 diabetes, it’s becoming increasingly important to understand the relation of type 1 diabetes to the risk of dementia.”

Advertisement

The study adds to prior evidence, including a 2025 Swedish nationwide registry analysis of over 43,000 people with type 1 diabetes showing a roughly twofold higher risk (HR 2.02 for all-cause dementia) over 14 years, with particularly elevated vascular dementia (HR 3.73). That research identified additional risk factors like higher HbA1c, systolic blood pressure, cardiovascular history, stroke/transient ischemic attack, lower education, single status and longer diabetes duration.

Mechanisms linking diabetes to dementia remain under study. Chronic hyperglycemia may damage blood vessels and promote inflammation, contributing to vascular dementia and cognitive decline. Hypoglycemia episodes, more common in type 1 due to insulin therapy, could also play a role by causing brain injury over time. Type 1’s autoimmune nature and earlier onset might amplify long-term brain effects compared with type 2, often tied to insulin resistance and metabolic syndrome.

The U.S. study’s shorter follow-up contrasts with longer-term cohorts but benefits from diverse representation through All of Us, aiming to address underrepresentation in research. Limitations include reliance on electronic records (potential misclassification), short observation period (limiting detection of slower-onset dementias) and exclusion of some dementia subtypes like frontotemporal or Lewy body.

Experts emphasize the association does not prove causation. “This study shows an association and does not prove that diabetes causes dementia,” the American Academy of Neurology noted in its release. Researchers called for further investigation into mechanisms, including potential roles of glycemic variability, insulin therapy and neuroprotective strategies.

Advertisement

For patients and clinicians, the findings underscore proactive brain health measures. Good glycemic control, blood pressure management, cardiovascular risk reduction, regular cognitive screening and lifestyle interventions — exercise, diet, social engagement — may help mitigate risks. As type 1 populations age, with more reaching 65+, targeted prevention becomes critical.

The results align with growing recognition of diabetes as a modifiable dementia risk factor. Previous meta-analyses and cohorts have linked type 2 to 50-100% higher odds, but type 1 data were scarcer until recent large-scale efforts.

As the global population with type 1 diabetes grows older thanks to better management, studies like this highlight the need for integrated care addressing both metabolic and neurological health. Future research may explore whether advanced insulin pumps, continuous glucose monitoring or emerging therapies reduce long-term brain risks.

Advertisement
Continue Reading

Business

‘ARIRANG’ Album Earns Praise for Visuals and Message

Published

on

SANTOS BRAVOS

SEOUL — BTS unleashed their highly anticipated full-group comeback with the release of their fifth studio album “ARIRANG” on March 20, 2026, and the official music video for lead single “SWIM” quickly became a global sensation, amassing over 36 million views on YouTube within its first day while topping trending charts worldwide.

BTS 'SWIM' Official MV
BTS ‘SWIM’ Official MV

Directed by acclaimed Spanish filmmaker Tanu Muiño and starring American actress Lili Reinhart, the “SWIM” MV delivers a sweeping, cinematic narrative set against the vast ocean. Filmed on a massive sailing ship in Lisbon, Portugal, the video blends high-seas drama with introspective moments, featuring all seven members — RM, Jin, Suga, j-hope, Jimin, V and Jung Kook — navigating ropes, steering through waves and reflecting on perseverance amid life’s challenges. Reinhart appears as a central figure facing personal turmoil, with BTS encouraging her metaphorical “swim” forward, symbolizing resilience and forward momentum.

The production, overseen by HYBE Chairman Bang Si-hyuk, showcases overwhelming scale and visual beauty through intricate sets, dynamic camera work and stunning ocean backdrops. Credits highlight an UnderWonder Content Production with Jason Baum as producer, and music helmed by Tyler Spry and Leclair. The track itself is an alternative pop anthem with a minimalist, repetitive chorus — “Swim, swim / Water falling off your skin” — that builds into an uplifting message of enduring obstacles without stopping.

Fans and critics have lauded the MV’s maturity and emotional depth. Billboard described it as “a cinematic experience” that sees the members “work the ropes and navigate a sailing ship,” emphasizing its high-seas drama. ARMY reactions flooded social media, with many calling it “beautiful” and “peak BTS visuals,” praising the aesthetic, vibes and how it captures the group’s evolution after a nearly four-year hiatus from full-album releases. One popular reaction video noted the MV’s prettiness but expressed a desire for more intense choreography, while others highlighted the song’s subtle charm that grows with repeated listens.

Advertisement

Jimin explained the track’s meaning in pre-release comments, saying it reflects BTS’s current mindset: “still moving forward” despite challenges. V admitted initially finding “SWIM” “unstimulating” but noted its lasting appeal, while RM revealed the group deliberated longest over selecting it as the title track, underscoring its thoughtful fit for this era. The lyrics encourage embracing life’s waves, with lines like “I could spend a lifetime watching you swim” evoking support and admiration.

The video’s rapid success — surpassing 5 million views in the first hour and becoming the most-liked music video of 2026 on YouTube in under three hours — underscores ARMY’s fervor for BTS’s return. It hit #1 on YouTube’s music trending chart shortly after premiere at 1 p.m. KST (0 a.m. ET) on March 20, coinciding with “ARIRANG”‘s drop. The 14-track album draws its name from the traditional Korean folk song “Arirang,” exploring themes of identity, longing, separation and reunion.

“SWIM” stands out for its understated production: a simple, monotone yet catchy hook anchors the verses, avoiding bombastic drops in favor of emotional resonance. Reviews like The Bias List called it “fine” in a year of solid but not revolutionary K-pop releases, appreciating its repetition without overstimulation. Fan discussions on Reddit noted the song’s strength contrasting some feelings that the MV felt “underwhelming” compared to expectations, though album production overall earned high marks as “peak” BTS.

The comeback extends beyond the MV. BTS is set for a special concert at Gwanghwamun Square in Seoul on March 21, 2026, with a world tour planned across 34 regions, including Australian dates in 2027. The release marks their first full-group album since before military service hiatuses, symbolizing reunion and renewed artistic direction.

Advertisement

As “SWIM” continues climbing charts and inspiring covers, reactions and fan theories, it solidifies BTS’s ability to blend grand visuals with introspective messaging. In a statement tied to the era, the group emphasized perseverance — a theme mirrored in the video’s nautical journey — reminding listeners that even in turbulent waters, the key is to keep swimming.

With the album receiving widespread acclaim for its depth and the MV’s stunning execution, “SWIM” has set a high bar for BTS’s 2026 chapter, proving their enduring global impact.

Continue Reading

Business

Smallcaps shine! 10 stocks that delivered gains of up to 41% this week. How many do you have?

Published

on

The Economic Times

Despite weak broader markets and rising geopolitical tensions, select smallcap stocks delivered sharp gains this week, with some surging over 40%. The rally highlights pockets of strength in sectors like chemicals, energy, and industrials, even as inflation concerns and global uncertainties continue to weigh on overall market sentiment.

Continue Reading

Business

Our Top 10 High Growth Dividend Stocks – March 2026

Published

on

Our Top 10 High Growth Dividend Stocks - March 2026

This article was written by

Financially Free Investor is a financial writer with 25 years investment experience. He focuses on investing in dividend-growing stocks with a long-term horizon. He applies a unique 3-basket investment approach that aims for 30% lower drawdowns, 6% current income, and market-beating growth on a long-term basis and he focuses on dividend-growing stocks with a long-term horizon.
He runs the investing group High Income DIY Portfolios which provides vital strategies for portfolio management and asset allocation to help create stable, long-term passive income with sustainable yields. The service includes a total of 10 model portfolios with a range of income targets for varying levels of risk, buy and sell alerts, and live chat. Learn more.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, BME, BST, CHI, DNP, USA, UTF, UTG, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or a recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Riley Exploration delivers 60% return after Fair Value signal

Published

on


Riley Exploration delivers 60% return after Fair Value signal

Continue Reading

Business

Howmet Aerospace: Flying Too High, Some Turbulence To Be Expected

Published

on

Howmet Aerospace: Flying Too High, Some Turbulence To Be Expected

Howmet Aerospace: Flying Too High, Some Turbulence To Be Expected

Continue Reading

Business

Dizal’s lung cancer drug meets primary goal in phase 3 trial

Published

on


Dizal’s lung cancer drug meets primary goal in phase 3 trial

Continue Reading

Business

Fans Praise Euphoric Vibes on Debut EP ‘DUAL’ Track

Published

on

SANTOS BRAVOS

Emerging Latin American boy group SANTOS BRAVOS released the official lyric video for “MHM” on March 18, 2026, drawing immediate acclaim for its dreamy visuals and uplifting energy as part of their debut EP “DUAL.” The track, a standout from the six-song project dropped March 13 under HYBE Latin America, has quickly become a fan favorite, amassing over 1.2 million views on YouTube within days while sparking widespread positive reactions across platforms.

SANTOS BRAVOS
SANTOS BRAVOS

Directed by Alejandro Bernal with editing by Mario Trujillo and color grading by Ana María Ormaza, the lyric video features soft, ethereal aesthetics — floating text synced to airy synths, pastel tones and subtle animations that evoke romance and lightness. Presented by HYBE Latin America, it ties into the EP’s dual identity: “Santo” side rooted in melodic Latin pop and “Bravo” in reggaetón-EDM intensity. “MHM” leans firmly into the former, delivering a breezy, feel-good sound with minimalistic production that highlights sweet vocals and catchy repetition.

The song opens with lines like “Esos ojitos caramelo / Con ese pelo combinan” (“Those caramel eyes / Go perfectly with that hair”), painting a flirtatious scene of admiration. The chorus builds around the titular “Mhm,” a hummed affirmation of attraction and desire, layered over soft percussion and shimmering synths. Clocking in at 2:19, “MHM” stands out for its understated charm — no explosive drops, just smooth, hypnotic flow that invites repeated listens. Lyrics by Spread LOF Rios and Caroline Ailin, with composition by Johnny Goldstein and others, capture youthful infatuation with poetic simplicity.

Fan reactions have been overwhelmingly enthusiastic. YouTube comments and reaction videos describe it as “brightening my heart” and “my favorite from the EP,” with viewers noting its sweet vocals and emotional warmth. One reactor called it “euphoric” and “the one that changes favorites daily,” praising how it grows on listeners. TikTok clips and Instagram reels show fans lip-syncing and dancing to the hook, while Reddit discussions highlight Kauê’s vocal delivery as a highlight. The video’s Paris-filming connection — tied to a Paris Fashion Week performance in January 2026 — adds behind-the-scenes intrigue.

“MHM” follows the group’s momentum from earlier releases. Debut single “0%” (October 2025) introduced their sound, while “KAWASAKI” exploded with over 33 million YouTube views for its club-ready energy. “DUAL” — featuring “0%,” “KAWASAKI,” “MHM,” “FE,” “WOW” and “Velocidade” — showcases versatility, earning praise in Billboard’s Latin music poll as fans’ top new release of the week. The EP topped fan-voted charts, with “MHM” positioned as a focus track for its melodic contrast to bolder cuts.

Advertisement

SANTOS BRAVOS formed through the HYBE Latin America reality series of the same name, which documented 17 trainees from Latin America, the U.S. and Spain in a K-pop-inspired program. The final five — Drew Venegas (U.S., 25), Alejandro Aramburú (Peru, 21), Gabi Bermúdez (Puerto Rico), Kauê Penna (Brazil, 19) and Kenneth Lavíll (Mexico) — debuted October 21, 2025, at Mexico City’s Auditorio Nacional. The group represents diversity and duality, with Drew bringing queer visibility as an out and proud member.

The lyric video release coincides with promotional pushes, including a weekly docuseries “detrás de DUAL” (Behind DUAL) on Spotify starting March 15, offering intimate looks at the EP’s creation. Grooming credits for the video went to stylist Charley McEwen using Oribe products, underscoring the polished visual identity.

Critics and fans alike note “MHM”‘s role in broadening SANTOS BRAVOS’ appeal. While “KAWASAKI” targets clubs, “MHM” offers emotional depth, appealing to listeners seeking romance and lightness in Latin pop. Reactions emphasize its replay value — “non-stop listening” is a common phrase — and how it complements the EP’s range.

As HYBE expands globally, SANTOS BRAVOS positions as a bridge between K-pop training rigor and Latin influences. The lyric video’s success signals strong fan engagement, with streams climbing on Spotify (474,773+ for “MHM”) and Apple Music. Upcoming plans include more content, potential remixes and live performances to sustain the buzz.

Advertisement

With “MHM” solidifying their place in the Latin pop scene, SANTOS BRAVOS continues building on a promising debut year. The track’s gentle euphoria and heartfelt delivery make it a bright spot in 2026’s emerging releases, proving the group’s ability to balance high-energy anthems with tender moments.

Continue Reading

Trending

Copyright © 2025